Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial

Name: Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial
Creator: Yan Zhao
Published: 2024-07-12T14:44:10.595Z
Keywords: Atopic Dermatitis

Zhao, Yan; Zhang, Litao; Zhang, Jianzhong

doi:10.17632/27f6zxm563.1

Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial

Published: 12 July 2024| Version 1 | DOI: 10.17632/27f6zxm563.1

Contributors:

Yan Zhao, Litao Zhang, Jianzhong Zhang

Description

Supplementary Materials for "Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial".

Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial

Description

Files

Categories

Licence